TCM
BCRX icon

TCG Crossover Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

TCG Crossover Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110M Hold
11,020,968
– – 2.65% 12
2026
Q1 		$105M Buy
+11,020,968
New +$85.6M 3% 9

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TCG Crossover Management's BCRX Position: Q2 2026 in Review

TCG Crossover Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 11,020,968 shares worth $110M. The position accounts for 2.65% of the portfolio, ranked #12.

TCG Crossover Management first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • TCG Crossover Management held 11,020,968 shares of BioCryst Pharmaceuticals worth $110M as of Q2 2026.
  • TCG Crossover Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up 2.65% of TCG Crossover Management's portfolio in Q2 2026, its #12 holding.
  • TCG Crossover Management first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.